Utility of 123-I ioflupane SPECT in the assessment of patients with parkinsonian syndrome and cerebral vasculopathy;SPECT con ioflupano I-123 en la catalogación de pacientes con síndrome parkinsoniano y vasculopatía cerebral

Revista Espanola de Medicina Nuclear

Volumn 24, Issue 6, 2005, Pages 392-403

  Garcia Vicente A M ^a   Vaamonde Cano, J ^a   Soriano Castrejon A ^a   Martinez Delgado C ^a   Talavera Rubio, P ^a   Poblete Garcia V M ^a   Ruiz Solis S ^a   Rodado Marina, S ^a   Cortes Romera M ^a  

^a Servicio de Cirugía General   (Spain)

Author keywords

123 I Ioflupane; Brain SPECT; Cerebral vasculopathy; Vascular parkinsonism

Indexed keywords

IODINE 123; IOFLUPANE I 123; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRAIN ISCHEMIA; BRAIN SCINTISCANNING; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; FEMALE; FOLLOW UP; FUNCTIONAL ANATOMY; HUMAN; IDIOPATHIC DISEASE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 30944445581     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0212-6982(05)74184-7     Document Type: Article

References (55)

1. Critchley M. Arteriosclerotic parkinsonism. Brain. 1929;52:23-83.
2. Yamanouchi H, Nagura H. Neurological signs and frontal white matter lesions in vascular parkinsonism. Stroke. 1997;28:965-9.
3. Reider-Groswasser I, Bornstein NM, Korczyn AD. Parkinsonism in patients with lacunar infarcts of the basal ganglia. Eur Neurol. 1995;35:46-9.
4. Van Zagten M, Lodder J, Kessels F. Gait disorder and parkinsonian signs in patients with strole related to small deep infarcts and white matter lesions. Mov Disord. 1998;13:89-95.
5. Chang CM, Yu YL, Leung SY, Fong KY. Vascular pseudoparkinsonism. Acta Neurol Scand. 1992;86:588-92.
6. Murrow RW, Schweiger GD, Kepes JJ, Koller WC. Parkinsonism due to a basal ganglia lacunar state: Clinicopathologic correlation. Neurol. 1990;40:897-900.
7. Zijlmans JCM, Thijssen HOM, Vogels OJM, Kremer HPH, Poels PJE, Schoolnderwaldt HC, et al. MRI in patients with suspected vascular parkinsonism. Neurology. 1995;45:2183-8.
8. Inzelberg R, Bornstein NM, Reider I, Korczyn AD. Basal ganglia lacunes and parkinsonism. Neuroepidemiology. 1994;13:108-12.
9. FitzGerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord. 1989;4:249-60.
10. Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999;56:98-102.
11. Foltynie T, Barker R, Brayne C. Vascular parkinsonism: a review of the precision and frequency of the diagnosis. Neuroepidemiology. 2002;21:1-7.
12. De Rijk MC, Breteler CT, Bea MM. Prevalence of parkinsonism and parkinson's disease in Europe: the Europarkinson Collaborative Study. J Neurol Neurosurg Psyquiatry. 1997;62:10-5.
13. Benito-Leon J, Bermejo-Pareja F, Rodríguez J, Molina JA, Gabriel R, Morales JM. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord. 2003;18:267-74.
14. Bower JH, Dickson DW, Taylor L, Maraganore DM, Rocca WA. Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov Disor. 2002;17:910-6.
15. Baldereshi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, et al. Pakinson's disease and parkinsonism in a longitudinal study. Two fold higher incidence in men. Neurology. 2000;55:1358-63.
16. Reuck J, Sieben G, Coster W, Hecken H. Parkinsonism in patients with cerebral infarcts. Clin Neurol Neurosurg. 1980;82-83:177-85.
17. Mancardi GL, Romagnoli P, Tassinari T, Gandolfo C, Primavera A, Loeb C. Lacunae and cribriform cavities of the brain. Correlations with pseudobulbar palsy and parkinsonism. Eur Neurol. 1988;28:11-7.
18. Tolosa ES, Santamaria J. Parkinsonism and basal ganglia infarcts. Neurology. 1984;34:1516-8.
19. Trenkwalder C, Paulus W, Kratczyk S, Hawkwn M, Oertel WH. Postural stability differentiates "lower body" from idiopatic parkinsonism. Acta Neurol Scand. 1995;91:444-52.
20. Jellinger KA. Parkinsonim due to Binswanger's subcortical arteriosclerotic encephalopathy. Mov Disord. 1996;11:461-2.
21. Schwab RS, England AC. Parkinson syndrome due to various specific causes: En: Vinken RJ, Bruyn GW, editors. Handbook of Clinical Neurology. Vol 6. Diseases of the Basal Ganglia. Amsterdam, Netherlands: North-Holland; 1968. p. 227-47.
22. Sibon I, Tison F. Vascular parkinsonism. Current Opin in Neurol. 2004;17:49-54.
23. Gerschlager W, Bencsits G, Pirker W, Bloem B, Asenbaum S, Prayer D, et al. 123 I beta-CIT SPECT distinguishes vascular parkinsonism from parkinson's disease. Mov Disord. 2002;17:518-23.
24. Hamano T, Tsuchida T, Hirayama M, Fujiyamma J, Mutoh T, Yonekura Y, et al. Dopamine transporter SPECT in patients with Parkinson's disease. Kaku Igaku. 2000;37:125-9.
25. Sasaki T, Amano T, Hashimoto J, Itoh Y, Muramatsu K, Kubo A, et al. SPECT imaging using 123 I beta-CIT and 123 I-IBF in extrapyramidal diseases. No To Shinkei. 2003;55:57-64.
26. 99m-Tc-TRODAT-1. J Nucl Med. 2001;42:408-13.
27. Tohgi H, Takahashi S, Abe T, Utsugisawa K. Syntomatic characteristics of parkinsonism and the width of substantia nigra pars compacta on MRI according to ischemic changes in the putamen and cerebral white matter: implications for the diagnosis of vascular parkinsonism. Eur Neurol. 2001;46:1-10.
28. Tomonaga M, Yamanouchi H, Tohgi H, Kameyama M. Clinicopathologic study of progressive subcortical vascular encephalopathy (Binswanger Type) in the elderly. J Am Geriatr Soc. 1982;30:524-9.
29. Yamanouchi H. Loss of white matter oligodendrocytes and astrocytes in progressive subcortical vascular encephalopathy of Binswanger type. Acta Neurol Scand. 1991;83:301-5.
30. Thompson PD, Marsden CD. Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger's disease. Mov Disord. 1987;2:1-8.
31. Award IA, Johnson PC, Spetzler RF, Hodak JA. Incidental subcortical lesions identified on magnetic resonance imaging in the elderly, II: postmortem pathological correlations. Stroke. 1986;17:1090-7.
32. Leifer D, Buonanno FS, Richardson EP. Clinicopathologic correlations of cranial magnetic resonance imaging of periventricular white matter. Neurology. 1990;40:911-8.
33. Sibon I, Fenelon G, Quinn N, Tison F. Parkinsonismo vascular. J Neurology (edicion espanola). 2004;2:253-64.
34. Mark MH, Sage JI, Walters AS, Duvoisisn C, Miller DC. Binswanger's disease presenting as levo-dopa responsive parkinsonism: clinicopathologic study of three cases. Mov Disord. 1995;10:450-4.
35. Demirkiran M, Bozdemir H, Sarica Y. Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurol Scand. 2001;104:63-7.
36. Ling MJ, Aggarwal A, Morris J. Dopa-responsive parkinsonism secondary to right temporal lobe haemorrahage. Mov Disord. 2002;17:402-23.
37. Zijlmans JC, Daniel SE, Hughes AJ, Revesz T, Lees AJ. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord. 2004;19:630-40.
38. Tohgi H, Abe T, Saneki M, Yamazaki K, Murata T. Concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism compared to Parkinson's disease patients. J Neural Transm. 1997;104:441-9.
39. Zijlmans JC, Katzenschlager R, Daniel SE, Lees AJ. The L-dopa response in vascular parkinsonism. J Neurol Neurosurg Psychiatry. 2004;75:545-7.
40. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv Neurol. 1987;45:1-18.
41. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopatic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-4.
42. Piccini P, Pavese N, Canapicchi R, Paoli C, Del Dotto P, Puglioli M, et al. White matter hyperintensities in Parkinson's disease: clinical correlations. Arch Neurol. 1995;52:191-4.
43. Manila RT, Rinne UK. Arteriosclerosis, heredity and some previous infections in the etiology of Parkinson's disease: A case control study. Clin Neurol Neurosurgery Psychiatry. 1976;79:46-56.
44. Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study. Acta Neuropathol. 2003;105:415-9.
45. Dubinsky RM, Jankovic J. Progressive supranuclear palsy and the multi-infartc state. Neurology. 1987;37:570-6.
46. Papapetropoulos S, Ellul J, Argyriou A, Talelli P, Chroni E, Papapetropoulos P. The effect of vascular disease on late onset Parkinson's disease. Eur J Neurol. 2004;11:231-5.
47. Brake T, Djamshidian S, Bencsits G, Pirker W, Asembaum S, Podreka I. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol. 2000;247 Suppl 4:IV/2-7.
48. Peters S, Eising EG, Przuntek H, Müller T. Vascular parkinsonism: a case report and review of the literature. J Clin Neuroscience. 2001;8:268-71.
49. Terashi H, Nagata K, Hirata Y, Hatazawa J, Utsumi H. Study on dopamine D2 binding capacity in vascular parkinsonism. Rinsho Shinkeigaku. 2001;41:659-64.
50. Van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-B CIT SPECT. J Nucl Med. 1995;36:1175-81.
51. Lavalaye J, Booij J, Reneman L, Habraken JBA, van Royen EA. Effect of age and gender on dopamine transporter imaging with 123-I-FP-CIT SPECT in healthy volunteers. Eur J Nucl Med. 2000;27:867-9.
52. Mozley PD, Acton PD, Barraclough ED, Plossl K, Gur RC, Alavi A, et al. Effects of age on dopamine transporters in healthy humans. J Nucl Med. 1999;40:1812-7.
53. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Galley SJ, et al. Dopamine transporters decrease with age. J Nucl Med. 1996;37:554-9.
54. Curran T, Lang AE. Parkinsonian sindromes associated with hydrocephalus: case reports, a review of the literature, and pathophysiological hypotheses. Mov Disord. 1994;9:508-20.
55. Shahar E, Lambert R, Hwang PA, Hoffman HJ. Obstructive hydrocephalus induced parkinsonism. I: Decreased basal ganglia regional blood flow. Paediatric Neurol. 1998;4:117-9.